• Je něco špatně v tomto záznamu ?

Interferon gamma release assay has potential in the prediction of chronic graft-versus-host disease in recipients of myeloablative allogeneic hematopoietic stem cell transplantation with post-transplantation cyclophosphamide-based graft-versus-host disease prophylaxis

M. Šťastná-Marková, P. Pecherková, Š. Němečková, J. Kryštofová, Š. Vaníková, J. Vydra, K. Roubalová

. 2025 ; 88 (-) : 102166. [pub] 20241221

Jazyk angličtina Země Nizozemsko

Typ dokumentu časopisecké články, pozorovací studie

Perzistentní odkaz   https://www.medvik.cz/link/bmc25010058

BACKGROUND: The rate of immune reconstitution after allogeneic hematopoietic stem cell transplantation (allo-HSCT) plays the principal role in the development of serious post-transplant complications. However, the post-transplantation course has a significant impact on shaping the immune system of the recipient, per se, thus representing risk factors for subsequent unfavorable outcomes. The predictive power of an interferon gamma (IFNγ) release assay (IGRA) on graft-versus-host disease (GVHD) or hematological relapse in recipients of allo-HSCT treated with post-transplantation cyclophosphamide and the impact of these complications on the restoration of cellular immune responsiveness was evaluated. STUDY DESIGN: A prospective observational study in which 62 adult patients with myeloid hematological malignancies who underwent allo-HSCT with a myeloablative conditioning regimen combined with post-transplantation cyclophosphamide were enrolled. Clinical data were collected and the IGRA was performed before commencement of the conditioning regimen and for 12 months post-allo-HSCT. Multivariate Cox regression and logistic regression models with backward stepwise analyses were used to calculate the predictive values for acute or chronic GVHD, or hematological relapse. RESULTS: Pre-transplantation and early post-transplantation IGRA values and other selected covariables (age, diagnosis, relapse risk, conditioning type, pre-T lymphocyte count, and donor sex), enabled prediction of the 12-month incidence of chronic GVHD with positive and negative predictive values of 75 % and 88 %, respectively. However, the IGRA did not improve the predictive value for acute GVHD or hematological relapse. Patients with myelodysplastic syndrome (MDS) had a significantly lower pre-transplant IGRA value (p = 0.021) and a delayed IFNγ response in IGRA, post-HSCT, than patients with acute myeloid leukemia (AML) (p = 0.015 and p = 0.0063 for 3 and 4 months post-HSCT, respectively). CONCLUSIONS: The IGRA can be used to monitor the recovery of total cellular immunity, post-HSCT and it has shown potential for use in personalized post-transplantation care. In the multivariate backward stepwise logistic regression model, pre-and early post-transplantation IGRA values showed potential for predicting chronic GVHD. Patients with MDS had a significantly lower pre-transplantation IGRA value and delayed IFNγ response in IGRA, post-HSCT, than patients with AML.

Citace poskytuje Crossref.org

000      
00000naa a2200000 a 4500
001      
bmc25010058
003      
CZ-PrNML
005      
20250429134903.0
007      
ta
008      
250415e20241221ne f 000 0|eng||
009      
AR
024    7_
$a 10.1016/j.trim.2024.102166 $2 doi
035    __
$a (PubMed)39716645
040    __
$a ABA008 $b cze $d ABA008 $e AACR2
041    0_
$a eng
044    __
$a ne
100    1_
$a Šťastná-Marková, Markéta $u Transplantation and Intensive Care Unit, Institute of Hematology and Blood Transfusion, Prague, Czech Republic
245    10
$a Interferon gamma release assay has potential in the prediction of chronic graft-versus-host disease in recipients of myeloablative allogeneic hematopoietic stem cell transplantation with post-transplantation cyclophosphamide-based graft-versus-host disease prophylaxis / $c M. Šťastná-Marková, P. Pecherková, Š. Němečková, J. Kryštofová, Š. Vaníková, J. Vydra, K. Roubalová
520    9_
$a BACKGROUND: The rate of immune reconstitution after allogeneic hematopoietic stem cell transplantation (allo-HSCT) plays the principal role in the development of serious post-transplant complications. However, the post-transplantation course has a significant impact on shaping the immune system of the recipient, per se, thus representing risk factors for subsequent unfavorable outcomes. The predictive power of an interferon gamma (IFNγ) release assay (IGRA) on graft-versus-host disease (GVHD) or hematological relapse in recipients of allo-HSCT treated with post-transplantation cyclophosphamide and the impact of these complications on the restoration of cellular immune responsiveness was evaluated. STUDY DESIGN: A prospective observational study in which 62 adult patients with myeloid hematological malignancies who underwent allo-HSCT with a myeloablative conditioning regimen combined with post-transplantation cyclophosphamide were enrolled. Clinical data were collected and the IGRA was performed before commencement of the conditioning regimen and for 12 months post-allo-HSCT. Multivariate Cox regression and logistic regression models with backward stepwise analyses were used to calculate the predictive values for acute or chronic GVHD, or hematological relapse. RESULTS: Pre-transplantation and early post-transplantation IGRA values and other selected covariables (age, diagnosis, relapse risk, conditioning type, pre-T lymphocyte count, and donor sex), enabled prediction of the 12-month incidence of chronic GVHD with positive and negative predictive values of 75 % and 88 %, respectively. However, the IGRA did not improve the predictive value for acute GVHD or hematological relapse. Patients with myelodysplastic syndrome (MDS) had a significantly lower pre-transplant IGRA value (p = 0.021) and a delayed IFNγ response in IGRA, post-HSCT, than patients with acute myeloid leukemia (AML) (p = 0.015 and p = 0.0063 for 3 and 4 months post-HSCT, respectively). CONCLUSIONS: The IGRA can be used to monitor the recovery of total cellular immunity, post-HSCT and it has shown potential for use in personalized post-transplantation care. In the multivariate backward stepwise logistic regression model, pre-and early post-transplantation IGRA values showed potential for predicting chronic GVHD. Patients with MDS had a significantly lower pre-transplantation IGRA value and delayed IFNγ response in IGRA, post-HSCT, than patients with AML.
650    _2
$a lidé $7 D006801
650    12
$a nemoc štěpu proti hostiteli $x diagnóza $x prevence a kontrola $x etiologie $7 D006086
650    12
$a cyklofosfamid $x terapeutické užití $7 D003520
650    _2
$a mužské pohlaví $7 D008297
650    _2
$a ženské pohlaví $7 D005260
650    _2
$a dospělí $7 D000328
650    12
$a transplantace hematopoetických kmenových buněk $x škodlivé účinky $7 D018380
650    _2
$a lidé středního věku $7 D008875
650    12
$a příprava pacienta k transplantaci $x metody $7 D019172
650    _2
$a prospektivní studie $7 D011446
650    _2
$a chronická nemoc $7 D002908
650    _2
$a test pomocí interferonu gama $7 D059425
650    _2
$a homologní transplantace $7 D014184
650    _2
$a mladý dospělý $7 D055815
650    _2
$a hematologické nádory $x terapie $7 D019337
650    _2
$a senioři $7 D000368
650    _2
$a mladiství $7 D000293
650    _2
$a myeloablativní agonisté $x terapeutické užití $7 D019653
655    _2
$a časopisecké články $7 D016428
655    _2
$a pozorovací studie $7 D064888
700    1_
$a Pecherková, Pavla $u Department of Biostatistics, Institute of Hematology and Blood Transfusion, Prague, Czech Republic
700    1_
$a Němečková, Šárka $u Department of Immunology, Institute of Hematology and Blood Transfusion, Prague, Czech Republic
700    1_
$a Kryštofová, Jitka $u Department of Immunology, Institute of Hematology and Blood Transfusion, Prague, Czech Republic
700    1_
$a Vaníková, Šárka $u Department of Immunomonitoring and Flow Cytometry, Institute of Hematology and Blood Transfusion, Prague, Czech Republic
700    1_
$a Vydra, Jan $u Transplantation and Intensive Care Unit, Institute of Hematology and Blood Transfusion, Prague, Czech Republic
700    1_
$a Roubalová, Kateřina $u Department of Immunology, Institute of Hematology and Blood Transfusion, Prague, Czech Republic. Electronic address: kroubalova@centrum.cz
773    0_
$w MED00006022 $t Transplant immunology $x 1878-5492 $g Roč. 88 (20241221), s. 102166
856    41
$u https://pubmed.ncbi.nlm.nih.gov/39716645 $y Pubmed
910    __
$a ABA008 $b sig $c sign $y - $z 0
990    __
$a 20250415 $b ABA008
991    __
$a 20250429134859 $b ABA008
999    __
$a ok $b bmc $g 2311431 $s 1247139
BAS    __
$a 3
BAS    __
$a PreBMC-MEDLINE
BMC    __
$a 2025 $b 88 $c - $d 102166 $e 20241221 $i 1878-5492 $m Transplant immunology $n Transpl Immunol $x MED00006022
LZP    __
$a Pubmed-20250415

Najít záznam

Citační ukazatele

Nahrávání dat ...

Možnosti archivace

Nahrávání dat ...